Научно-исследовательский центр «Онкотераностика»

Публикации Толмачева В. М. с аффилиацией Центра

  1. Deyev, S. M., Xu, T., Liu, Y., Schulga, A., Konovalova, E., Garousi, J., Rinne, S. S., Larkina, M., Ding, H., Gräslund, T., Orlova, A., Tolmachev, V., & Vorobyeva, A. Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1 //Cancers.– 2021. – Vol. 13. – No. 14. – P. 3589. 
    DOI:10.3390/cancers13143589
    https://www.mdpi.com/2072-6694/13/14/3589
  2. Bragina, O., Chernov, V., Schulga, A., Konovalova, E., Garbukov, E., Vorobyeva, A., Orlova, A., Tashireva, L., Sorensen, J., Zelchan, R., Medvedeva, A., Deyev, S., & Tolmachev, V. Phase I trial of 99mTc-(HE)3-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer //Journal of nuclear medicine: official publication, Society of Nuclear Medicine.– 2021. – jnumed.121.262542. Advance online publication. 
    DOI:10.2967/jnumed.121.262542
    https://jnm.snmjournals.org/content/early/2021/08/12/jnumed.121.262542
  3. Xu, T., Vorobyeva, A., Schulga, A., Konovalova, E., Vorontsova, O., Ding, H., Gräslund, T., Tashireva, L. A., Orlova, A., Tolmachev, V., & Deyev, S. M. Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model //Cancers.– 2021. – Vol. 13. – No. 16. – P. 3939. 
    DOI:10.3390/cancers13163939
    https://www.mdpi.com/2072-6694/13/16/3939
  4. Rinne, S.S.; Leitao, C.D.; Abouzayed, A.; Vorobyeva, A.; Tolmachev, V.; Ståhl, S.; Löfblom, J.; Orlova, A. HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers. Cancers. – 2021. – Vol. 13.– P. 4791.
    DOI:10.3390/cancers13194791
    https://www.mdpi.com/2072-6694/13/19/4791
  5. Rinne, S. S., Orlova, A., & Tolmachev, V. PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology //International journal of molecular sciences. – 2021. – Vol. 22. – No. 7. – P. 3663.
    DOI: 10.3390/ijms22073663
    https://www.mdpi.com/1422-0067/22/7/3663
  6. Liu, Y., Vorobyeva, A., Xu, T., Orlova, A., Loftenius, A., Bengtsson, T., Jonasson, P., Tolmachev, V., & Frejd, F. Y. Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain  //Pharmaceutics.– 2021. – Vol. 13. – No. 6. – P. 839. 
    DOI:10.3390/pharmaceutics1306083
    https://pubmed.ncbi.nlm.nih.gov/34200197
  7. Bragina, O., von Witting, E., Garousi, J., Zelchan, R., Sandström, M., Orlova, A., Medvedeva, A., Doroshenko, A., Vorobyeva, A., Lindbo, S., Borin, J., Tarabanovskaya, N., Sörensen, J., Hober, S., Chernov, V., & Tolmachev, V. Phase I Study of 99mTc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer //Journal of nuclear medicine. – 2021. – Vol. 62. – No. 4. – P. 493–499.
    DOI:10.2967/jnumed.120.248799
    https://jnm.snmjournals.org/content/62/4/493
  8. Oroujeni, M., Rinne, S.S., Vorobyeva, A., Loftenius, A., Feldwisch, J., Jonasson, P., Chernov, V., Orlova, A., Frejd, F.Y., Tolmachev, V. Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake //International Journal of Molecular Sciences. – 2021. – Vol. 22. –  No. 2770.
    DOI:10.3390/ijms22052770 
    https://www.mdpi.com/1422-0067/22/5/2770
  9. Oroujeni, M., Xu, T., Gagnon, K., Rinne, S.S., Weis, J., Garousi, J., Andersson, K.G., Löfblom, J., Orlova, A. and Tolmachev, V. Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule  //Pharmaceutics. – 2021. – Vol. 13. –  No. 292.
    DOI: 10.3390/pharmaceutics13020292 
    https://www.mdpi.com/1999-4923/13/2/292
  10. Ding, H., Xu, T.,  Zhang, J., Tolmachev, V., Oroujeni, M., Orlova, A., Gräslund, T., Vorobyeva, A. Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution //Pharmaceutics. – 2021. – Vol. 13. –  No. 430.
    DOI: 10.3390/pharmaceutics13030430.
    https://www.mdpi.com/search?q=Affibody-Derived+Drug+&journal=pharmaceutics
  11. Abouzayed, A., Rinne, S. S., Sabahnoo, H., Sörensen, J., Chernov, V., Tolmachev, V., Orlova, A. Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer //Pharmaceutics. – 2021. – Vol. 13. – No. 2. – P. 182.
    DOI: 10.3390/pharmaceutics13020182  
    https://www.mdpi.com/1999-4923/13/2/182
  12. Rinne, S.S., Abouzayed, A., Gagnon, K., Tolmachev, V., Orlova, A. 66 Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66 Ga] Ga-NOTA-PEG 2-RM26 //Scientific reports. – 2021. – Vol. 11. – No. 1. – P. 1-12. 
    DOI: 10.1038/s41598-021-82995-7
    https://pubmed.ncbi.nlm.nih.gov/33574368
  13. Xu, T., Ding, H., Vorobyeva, A., Oroujeni, M., Orlova, A., Tolmachev, V.,  Gräslund, T.  Drug conjugates based on a monovalent affibody targeting vector can efficiently eradicate HER2 positive human tumors in an experimental mouse model //Cancers. – 2021. – Vol. 13. – No. 1. – P. 85. 
    DOI:10.3390/cancers13010085  
    https://www.mdpi.com/2072-6694/13/1/85
  14. Tano, H., Oroujeni, M., Vorobyeva, A., Westerlund, K., Liu, Y., Xu, T., Vasconcelos, D., Orlova, A., Karlström, A.E., Tolmachev, V. Comparative Evaluation of Novel 177Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting //Cancers. – 2021. – Vol. 13. – No. 3. – P. 500. 
    DOI: 10.3390/cancers13030500  
    https://www.mdpi.com/2072-6694/13/3/500
  15. Baun, C., Mitran, B., Rinne, S. S., Dam, J. H., Olsen, B. B., Tolmachev, V., Orlova, A. Thisgaard, H. Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer //Molecules. 2020. – Vol. 25. – No. 24. – P. 5993.
    DOI: 10.3390/molecules25245993 
    https://www.mdpi.com/1420-3049/25/24/5993
  16. Mitran B., Tolmachev V., Orlova A. Radiolabeled grpr antagonists for imaging of disseminated prostate cancer. Influence of labeling chemistry on targeting properties //Current medicinal chemistry. – 2020. – Vol. 27. – No. 41. – P. 7090-7111.
    DOI: 10.2174/0929867327666200312114902 
    https://www.ingentaconnect.com/content/ben/cmc/2020/00000027/00000041/art00013;jsessionid=1v764c8qjxtbk.x-ic-live-01
  17. Abouzayed, A., Tano, H., Nagy, Á., Rinne, S.S., Wadeea, F., Kumar, S., Westerlund, K., Tolmachev, V., Karlström, A.E., Orlova, A. Preclinical evaluation of the grpr-targeting antagonist rm26 conjugated to the albumin-binding domain for grpr-targeting therapy of cancer //Pharmaceutics. – 2020. – Vol. 12. – No. 10. – P. 977.
    DOI: 10.3390/pharmaceutics12100977 
    https://www.mdpi.com/1999-4923/12/10/977
  18. Tolmachev V., Orlova A., Sörensen J. The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer //Seminars in Cancer Biology. – Academic Press, 2021. 
    DOI: 10.1016/j.semcancer.2020.10.005 
    https://www.sciencedirect.com/science/article/
  19. Garousi, J., von Witting, E., Borin, J., Vorobyeva, A., Altai, M., Vorontsova, O., Konijnenberg, M.W., Oroujeni, M., Orlova, A., Tolmachev, V.  Hober, S. Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle //Biomaterials. – 2021. – Vol. 266. – P. 120381
    DOI:10.1016/j.biomaterials.2020.120381
    https://www.sciencedirect.com/science/article/pii/S014296122030627X
  20. Leitao, C.D., Rinne, S.S., Altai, M., Vorontsova, O., Dunås, F., Jonasson, P., Tolmachev, V., Löfblom, J., Ståhl, S., Orlova, A. Evaluating the therapeutic efficacy of mono-and bivalent affibody-based fusion proteins targeting HER3 in a pancreatic cancer xenograft model //Pharmaceutics. – 2020. – Vol. 12. – No. 6. – P. 551.
    DOI: 10.3390/pharmaceutics12060551
    https://www.mdpi.com/1999-4923/12/6/551
  21. Vorobyeva, A., Bezverkhniaia, E., Konovalova, E., Schulga, A., Garousi, J., Vorontsova, O., Abouzayed, A., Orlova, A., Deyev, S., Tolmachev, V. Radionuclide molecular imaging of EpCAM expression in triple-negative breast cancer using the scaffold protein DARPin Ec1 //Molecules. – 2020. – Vol. 25. – No. 20. – P. 4719.
    DOI: 10.3390/molecules25204719
    https://www.mdpi.com/1420-3049/25/20/4719
  22. Vorobyeva, A., Konovalova, E., Xu, T., Schulga, A., Altai, M., Garousi, J., Rinne, S.S., Orlova, A., Tolmachev, V., Deyev, S. Feasibility of imaging epcam expression in ovarian cancer using radiolabeled darpin ec1 //International Journal of Molecular Sciences. – 2020. – Vol. 21. – No. 9. – P. 3310.
    DOI: 10.3390/ijms21093310
    https://www.mdpi.com/1422-0067/21/9/3310/htm
  23. Ding, H., Altai, M., Yin, W., Lindbo, S., Liu, H., Garousi, J., Xu, T., Orlova, A., Tolmachev, V., Hober, S., Gräslund, T. HER2-specific pseudomonas exotoxin a pe25 based fusions: Influence of targeting domain on target binding, toxicity, and in vivo biodistribution //Pharmaceutics. – 2020. – Vol. 12. – No. 4. – P. 391.
    DOI: 10.3390/pharmaceutics12040391
    https://www.mdpi.com/1999-4923/12/4/391/htm
  24. Tolmachev, V., Orlova, A. Affibody molecules as targeting vectors for PET imaging //Cancers. – 2020. – Vol. 12. – No. 3. – P. 651.
    DOI: 10.3390/cancers12030651
    https://www.mdpi.com/2072-6694/12/3/651
  25. Rinne, S.S., Leitao, C.D., Saleh-Nihad, Z., Mitran, B., Tolmachev, V., Ståhl, S., Löfblom, J., Orlova, A. Benefit of later-time-point PET imaging of her3 expression using optimized radiocobalt-labeled affibody molecules  //International journal of molecular sciences. – 2020. – Vol. 21. – No. 6. – P. 1972.
    DOI: 10.3390/ijms21061972
    https://www.mdpi.com/1422-0067/21/6/1972
  26. Deyev, S.M., Vorobyeva, A., Schulga, A., Abouzayed, A., Günther, T., Garousi, J., Konovalova, E., Ding, H., Gräslund, T., Orlova, A., Tolmachev, V. Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1 //International Journal of Biological Macromolecules. – 2020. – Vol. 145. – P. 216-225.
    DOI: 10.1016/j.ijbiomac.2019.12.147
    https://www.sciencedirect.com/science/article/pii/S0141813019393808
  27. Rinne, S.S., Xu, T., Leitao, C.D., Ståhl, S., Löfblom, J., Orlova, A., Tolmachev, V., Vorobyeva, A. Influence of residualizing properties of the radiolabel on radionuclide molecular imaging of HER3 using affibody molecules //International Journal of Molecular Sciences. – 2020. – Vol. 21. – No. 4. – P. 1312.
    DOI: 10.3390/ijms21041312
  28. Altai, M., Vorobyeva, A., Tolmachev, V., Karlström, A.E., Westerlund, K. Preparation of Conjugates for Affibody-Based PNA-Mediated Pretargeting //Peptide Nucleic Acids. – Humana, New York, NY, 2020. – P. 283-304.
    DOI: 10.1007/978-1-0716-0243-0_18
  29. Larkina, M.S., Ozerskaya, A.V., Podrezova, E.V., Belousov, M.V., Tolmachev, V., Zhdankin, V.V., Yusubov, M.S. Efficient Synthesis of ω-[18F]Fluoroaliphatic Carboxylic Esters and Acids for Positron Emission //European Journal of Organic Chemistry. – 2020. – P. 6375-6381.
    DOI: 10.1002/ejoc.202000934
    https://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/ejoc.202000934
  30. Alhuseinalkhudhur, A., Lubberink, M., Lindman, H., Tolmachev, V., Frejd, F.Y., Feldwisch, J., Velikyan, I., Sörensen, J. Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer //EJNMMI research. – 2020. – Vol. 10. – No. 1. – P. 1-10.
    DOI: 10.1186/s13550-020-0603-9
    https://ejnmmires.springeropen.com/articles/10.1186/s13550-020-0603-9
  31. Lundmark, F., Abouzayed, A., Mitran, B., Rinne, S.S., Varasteh, Z., Larhed, M., Tolmachev, V., Rosenström, U., Orlova, A. Heterodimeric radiotracer targeting PSMA and GRPR for imaging of prostate cancer—optimization of the affinity towards PSMA by linker modification in murine model //Pharmaceutics. – 2020. – Vol. 12. – No. 7. – P. 614.
    DOI: 10.3390/pharmaceutics12070614
    https://www.mdpi.com/1999-4923/12/7/614
  32. Bragina, O.D., Vorobyeva, A.G., Tolmachev, V.M., Orlova, A.M., Chernov, V.I., Deyev, S.M., Proshkina, G.N., Shulga, A.A., Larkina, M.S., Medvedeva, A.A., Zelchan, R.V. In vitro and in vivo evaluation of the radiochemical compound based on 99m technetium labelled DARPin9_29 for molecular visualization of malignancies overexpressing Her2/neu [In vitro и in vivo оценка радиохимического соединения на основе меченного 99m-Tc каркасного белка  DARPin9_29 для молекулярной визуализации злокачественных образований с гиперэкспрессией Her2/neu] //Medical Radiology and Radiation Safety. – 2020. – Vol. 65. – No. 1. – P. 37-41.
    DOI: 10.12737/1024-6177-2020-65-1-37-41
    https://medradiol.fmbafmbc.ru/journal_medradiol/abstracts/2020/1/37-41_Bragina_et_al.pdf